跳至主要内容
临床试验/NL-OMON56570
NL-OMON56570尚未招募不适用

COBRA re-KAI study: COVID-19 vaccination in patients with reduced B-cell and T-cell immunity: response after re-vaccination of a kaleidoscopic group of hematological patients: what*s the impact? - COBRA-RE-KAI

Amsterdam UMC0 个研究点目标入组 250 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
250

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 64(—)

入选标准

  • Age >=18 years
  • Patient groups:
  • Patients who received:
  • 1. B cell depleting immunochemotherapy (n=50), at least 8 months after last
  • B-cel depleting therapy before first vaccination.6
  • 2. B cell depleting CAR T cell therapy (n=50); 3 months after treatment.6
  • 3. Patients who received autologous HCT (myeloablative chemotherapy: high dose
  • melphalan (HDM)) (n=50); 3 months after treatment before first vaccination 6.
  • 4. Patients who received autologous HCT (myeloablative chemotherapy:
  • BCNU-etoposide-Ara-C-Melphalan (BEAM) or BCNU-thiotepa) (n=50); at least 3
  • months after transplantation with a maximum of 6 months before first
  • vaccination. 6
  • Group 5: Patients who received allogeneic HCT (various indications) (n=50) 3
  • months after transplantation.

排除标准

  • - Unwilling or unable to give informed consent
  • - Known allergy to one of the components of the vaccine
  • - Patients with a life expectancy of < 12 months

研究者

发起方
Amsterdam UMC

相似试验